How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
In: BMJ (Clinical research ed.), Jg. 368 (2020-01-02), S. l6435
academicJournal
Zugriff:
Competing Interests: Competing interests: We have read and understood BMJ policy on declaration of interests and have the following interests to declare: SC, JB, FM, PJ, MB, and NC are all NICE employees. PC is an employee of NHS England. SP and LB declare no conflicts of interest.
Titel: |
How should we assess the clinical and cost effectiveness of histology independent cancer drugs?
|
---|---|
Autor/in / Beteiligte Person: | Cooper, S ; Bouvy, JC ; Baker, L ; Maignen, F ; Jonsson, P ; Clark, P ; Palmer, S ; Boysen, M ; Crabb, N |
Zeitschrift: | BMJ (Clinical research ed.), Jg. 368 (2020-01-02), S. l6435 |
Veröffentlichung: | London : British Medical Association, 2020 |
Medientyp: | academicJournal |
ISSN: | 1756-1833 (electronic) |
DOI: | 10.1136/bmj.l6435 |
Schlagwort: |
|
Sonstiges: |
|